Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice.
نویسندگان
چکیده
BACKGROUND Although clinical guidelines exist for optimal levels of serum markers of chronic kidney disease mineral and bone disorder (CKD-MBD), target parameters are not achieved in many haemodialysis (HD) patients. The reason for this evidence-practice gap is unclear and more information from patients and healthcare professionals is required to improve knowledge transfer. We aimed to determine potential barriers by surveying HD patients and staff about awareness and management of CKD-MBD. METHODS A total of 136 prevalent HD patients, 25 nephrologists and 58 dialysis nurses/technicians were surveyed. Three separate questionnaires included issues of knowledge and awareness of CKD-MBD and factors limiting management (including compliance, medications and general understanding). RESULTS Of patients surveyed, 84% had heard of phosphate, but 42% were unsure of high phosphate foods and 46% unaware of consequences of elevated phosphate. Twenty-seven percent and thirty-five percent of patients, respectively, had difficulty taking or forgetting to take phosphate binders. Seventy-four percent of patients wanted to know more about CKD-MBD (40% via written material). Of nephrologists surveyed, 76% thought non-compliance with phosphate binders was the main reason for poor control of phosphate (predominantly related to poor patient understanding); 84% thought patients wanted to know more but only 28% provided written material on CKD-MBD. Of dialysis staff surveyed, 63% thought non-compliance with binders explained poor control, the main reason being lack of patient understanding; 88% thought patients wanted to know more but only 17% provided written education. CONCLUSIONS Implementation of an intensive educational programme, with a multi-faceted approach, for HD patients may promote better control of CKD-MBD and improve achievement of target levels.
منابع مشابه
“ Clinical pattern of bone mineral derangements , if any ( High bone turnover disease / Low bone turnover disease ) in CKD Patients undergoing Haemodialysis ”
Chronic kidney disease related mineral and bone disease (CKD-MBD) is a worldwide challenge in haemodialysis patients associated with high morbidity and mortality. CKD-MBD, the new terminology used for Renal Osteodystrophy and Renal bone disease (KDIGO).In clinical practice, bone biopsy is used infrequently to detect MBD in CKD, because it is an invasive and often expensive procedure and the sam...
متن کاملCOSMOS: the dialysis scenario of CKD-MBD in Europe.
BACKGROUND Chronic kidney disease-mineral and bone disorders (CKD-MBD) are important complications of CKD5D patients that are associated with mortality. METHODS COSMOS is a multicentre, open cohort, prospective, observational 3-year study carried out in haemodialysis patients from 20 European countries during 2005-07. The present article describes the main characteristics of the European dial...
متن کاملCan we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts.
Assessing bone turnover is a key diagnostic tool in the global management of chronic kidney disease-mineral and bone disorder (CKD-MBD). Since bone biopsy is invasive and cannot be repeated in clinical practice and because bone histomorphometry is less available due to the lack of specialized laboratories, we will focus on potential biomarkers used to assess and monitor bone turnover. After bri...
متن کاملChronic kidney disease-mineral and bone disorder KDIGO guidelines.
• one measure of the skeletal component of the systemic disorder of CKD-MBD that is quantifiable by histomorphometry of bone biopsy. The guidelines themselves focussed on three key domains relating to: (1) diagnosis of CKD-MBD with respect to biochemical abnormalities, bone and vascular calcification, 2009 saw the publication of the clinical practice guidelines from Kidney Disease Improving Glo...
متن کاملImpact of cinacalcet introduction on MBD management: the MBD-5D study in Japan
Chronic kidney disease-mineral and bone disorder (CKD-MBD) has recently attracted attention in light of its association with clinical outcomes, such as fracture, cardiovascular disease, and mortality. Management of CKD-MBD has therefore come to have a central role in dialysis practice. Cinacalcet, a newly developed drug, has changed prescription patterns in many centers based on different chang...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
دوره 26 4 شماره
صفحات -
تاریخ انتشار 2011